# Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual

> **NCT05339256** · PHASE2 · NOT_YET_RECRUITING · sponsor: **New York State Psychiatric Institute** · enrollment: 50 (estimated)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** Buprenorphine SL
- **OTHER:** Telehealth
- **OTHER:** In-person treatment as usual

## Key facts

- **NCT ID:** NCT05339256
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05339256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05339256, "Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05339256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*